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parameters, including geometric uncertainties, from a large 
cohort of patients. 
Materials and Methods: Multi-institutional data of 693 NSCLC 
patients of which 530 SBRT (stage-I) , and 163 treated with 
concurrent chemoradiation (CCRT) with volumetric image 
guidance in all fractions with DVHs of PTV and GTV and their 
corresponding local control rates at two year were available 
for this analysis. The prescription dose in the CCRT regiment 
was 24x2.75Gy with daily low-dose Cisplatin. The sensitizing 
effect of chemotherapy was accounted for in the TCP model 
by using a correction factor of 1.17 to total surviving fraction 
of cells at the end of treatment. In the SBRT patients, doses 
varying from 37.5 to 60 Gy were delivered in two to 10 
fractions. The median follow-up was 1.13 and 1.5 years 
respectively in the CCRT and SBRT regiments. In method one 
of this study, the DVH and volume of the GTV is used to 
estimate the population average radiosensitivity ( ),its 
standard deviation (σα) and equivalent uniform dose (EUD) ‘a’ 
parameters in the ‘Marsden TCP’ model. In method two, the 
dose of the PTV and the volume of the GTV (to calculate the 
total clonogens in the GTV) were used to account for day-to-
day geometric uncertainties. The α/β value and clonogen 
density was fixed to 10 Gy and 1e7 cells/cc respectively in 
both methods. The two methods were compared with the 
Akaike information criterion (AIC). To test the validity of the 
combined SBRT+CCRT TCP modeling, these two regiments 
were also modelled with separate , σα and ‘a’ 
parameters. The likelihood-ratio test was used to calculate 
the p-value between the separate and combined models. 
Results: The best-fit parameters are given in table 1 along 
with their 95% confidence intervals calculated with profile-
likelihood method for both methods. The , σα are almost 
equal in both methods while the EUD ‘a’ parameter 
approaching PTV mean dose and GTV minimum dose. The PTV 
based model was superior to the GTV based model with an 
AIC difference of 32.8 units. Separate analysis of SBRT and 
CCRT did not yield a superior TCP model (p=0.28).  
 
 
 
 
Conclusions: The tumor control probability of 
chemoradiation and SBRT regiments were successfully 
described by a single model. Separate analysis of 
chemoradiation and SBRT regiments did not improve the 
model. An EUD approaching the PTV mean dose best 
described the TCP indicating that geometric uncertainties 
play a role despite accurate image guidance.  
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Purpose/Objective: Dose-response modelling of sexual 
dysfunction after radiotherapy (RT) for prostate cancer has 
so far mainly focused on relationships between dose to the 
penile bulb (PB) and erectile dysfunction. However, 
radiation-induced sexual dysfunction involves the interplay 
between various symptoms and critical structures. In this 
study we hypothesized that dose to the corpora cavernosa 
(CC), alone or in combination with the PB (CC+PB), better 
explains the occurrence of interacting symptoms on sexual 
dysfunction than dose to the PB exclusively.  
Materials and Methods: To identify interacting symptoms, 
i.e. symptom groups, we applied factor analysis (FA) to 16 
patient-reported symptoms on sexual dysfunction in three 
cohorts (N=372). The investigated subjects were previously 
treated for localized prostate cancer either with primary or 
salvage external beam RT (EBRT or POSTOP), or EBRT 
combined with brachytherapy in 1993-2006 (time to follow-
up: 1-14 years; average age at RT: 64-70 years). Prescribed 
dose was 70 Gy@2.0 Gy/fraction. The ability of maximum and 
mean absorbed dose (Dmax or Dmean; population median of 
Dmean: CC=50 Gy, PB=67 Gy, CC+PB=51 Gy) in CC, PB, and 
CC+PB to predict single/joint symptoms in identified 
symptom groups was studied for EBRT and POSTOP (logistic 
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regression and the Area Under the Receiver Operating Curve 
(Az)). 
Results: Of three distinct symptom groups identified in all 
cohorts, labelled Erectile dysfunction (ED), Orgasm 
dysfunction, and Pain, dose to CC, PB, and CC+PB was 
associated (p≤0.05) with symptoms in ED. For the EBRT 
cohort, prediction of any ED symptom/symptoms was the 
highest with CC Dmax (Az=0.83; p=0.002). Weaker, but still 
significant, relationships were found also with CC+PB and PB 
Dmax, as well as with CC+PB Dmean (Az=0.72-0.74; p=0.02-0.04). 
For the POSTOP cohort, CC and CC+PB Dmean predicted one ED 
symptom (Az=0.65-0.66; 0.02-0.03).  
Conclusions: Based on patient-reported symptoms on sexual 
dysfunction from two cohorts, our results suggest that dose 
to the corpora cavernosa, alone or in combination with the 
penile bulb may be critical for erectile dysfunction following 
EBRT for localized prostate cancer. By uncovering the 
interactions between symptoms as well as how they can be 
explained by dose to the investigated structures, our findings 
have the potential to contribute to a better understanding of 
the underlying radiation-induced causes for sexual 
dysfunction.  
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Purpose/Objective: Preoperative chemoradiotherapy for 
rectal cancer reduces the risk of local recurrence, but also 
induces gastrointestinal (GI) toxicity. Acute GI toxicity might, 
in addition to the discomfort caused to patients, threaten 
treatment compliance. Modern radiotherapy techniques, such 
as intensity modulated radiotherapy (IMRT), can reduce dose 
delivered to the bowel, potentially limiting acute GI toxicity. 
Previous studies have reported dose-volume relationships for 
acute GI toxicity for patients treated with 3D conformal 
techniques (3D-CRT), but few have examined patients 
treated with IMRT. 
Materials and Methods: We explored dose metrics 
correlating with acute diarrhea and chemotherapy 
compliance for a single-institution cohort of rectal cancer 
patients (n=115) treated with IMRT. Acute diarrhea during 
treatment was scored prospectively by trained RT nurses 
(CTCAE v3.0). The highest toxicity score was used for 
analysis. Treatment charts were retrospectively reviewed for 
chemotherapy compliance; defined as no treatment 
interruptions, discontinuations, or dose reductions. The 
entire intestinal cavity containing small bowel loops up to the 
upper level of L5 was delineated by experienced radiation 
oncologists. IMRT treatment planning used a 5- or 7-field 
technique with 6 MV photon beams. Most patients were given 
60 Gy in 30 fractions to the tumour and 50 Gy in 30 fractions 
to lymph node targets, and many received an additional 
tumour boost (either external beam or brachytherapy). 
Ordinal and binary logistic modelling was used to correlate 
absolute volumes of intestinal cavity receiving x Gy or above 
(Vx) to graded toxicity scores and chemotherapy treatment 
compliance. Optimal value of the dose cut-off x was chosen 
by maximum likelihood technique accounting for scanning the 
cut-point. Clinical factors (see Table 1) were included one by 
one in both models to examine their association with 
toxicity. Significance levels were estimated using likelihood 
ratio tests. 
 
 
Results: V32Gy correlated with acute diarrhea (p=0.0001), see 
Fig 1a; females had an increased risk of toxicity (OR=2.13, 
95% CI 1.03–4.42, p=0.04). V46Gy correlated with 
chemotherapy compliance (p=0.005, 100 patients receiving 
concurrent chemotherapy), see Fig 1b. Women had lower 
treatment compliance (OR=2.41, 1.09–5.34, p=0.03), as had 
patients with low BMI (OR=0.89, 0.80–0.99, for 1 point 
increase in BMI, p=0.03) and patients with diabetes (OR=7.29, 
1.21–43.8, p=0.03). Age, brachytherapy boost, prior 
abdominal surgery, smoking history, or domestic status had 
no influence on any of the two endpoints, nor had concurrent 
chemotherapy on the risk of acute diarrhea. 
